SCHEMBL5294174

SCHEMBL5294174

CN(CC(=O)O)C(=O)Cc1ccccc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.54
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
LTB4R Q15722 4/20 0.50
LTB4R2 Q9NPC1 4/20 0.50
CHRM2 P08172 1/20 0.49
CHRM4 P08173 1/20 0.49
CHRM5 P08912 1/20 0.49
CHRM1 P11229 1/20 0.49
CHRM3 P20309 1/20 0.49
ALOX5 P09917 1/20 0.49
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
F2 P00734 1/20 0.48
KMT2A Q03164 1/20 0.47
CA12 O43570 1/20 0.47
CA9 Q16790 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1516137 0.82 NPC1 (0.75) NPC1RAB9AKMT2ACA12CA9
SCHEMBL8569413 0.82 NPC1 (0.53) AKR1B1NPC1RAB9ALTB4RLTB4R2
SCHEMBL7374914 0.81 KMT2A (0.72) NPC1RAB9AALOX5F2KMT2A
SCHEMBL4421574 0.80 NPC1 (0.66) AKR1B1NPC1RAB9ALTB4RLTB4R2
SCHEMBL339507 0.79 CES2 (0.56) AKR1B1NPC1RAB9ALTB4RLTB4R2
SCHEMBL9122526 0.79 LTB4R (0.56) NPC1RAB9ALTB4RLTB4R2CHRM2
SCHEMBL14415480 0.79 LTB4R (0.56) NPC1RAB9ALTB4RLTB4R2CHRM2
SCHEMBL15775863 0.78 AKR1B1 (0.56) AKR1B1ALOX5CES2CES1KMT2A
SCHEMBL7750313 0.78 CHRM2 (0.57) AKR1B1NPC1RAB9ALTB4RLTB4R2
SCHEMBL5144362 0.78 LTB4R (0.55) NPC1RAB9ALTB4RLTB4R2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO disclosed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 AKR1B1 4248/4885NPC1 4197/4885RAB9A 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.